This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Whitehouse, A. S. Articles by Tisdale, M. J. Search for Related Content PubMed PubMed Citation Articles by Whitehouse, A. S. Articles by Tisdale, M. J.

Mechanism of Attenuation of Skeletal Muscle Protein Catabolism in Cancer Cachexia by Eicosapentaenoic Acid¹

Pharmaceutical Sciences Research Institute, Aston University, Birmingham B4 7ET, United Kingdom

Cancer cachexia is characterized by selective depletion of skeletal muscle protein reserves. Soleus muscles from mice bearing a cachexia-inducing tumor (MAC16) showed an increased protein degradation in vitro, as measured by tyrosine release, when compared with muscles from nontumor-bearing animals. After incubation under conditions that modify different proteolytic systems, lysosomal, calcium-dependent, and ATP-dependent proteolysis were found to contribute to the elevated protein catabolism. Treatment of mice bearing the MAC16 tumor with the polyunsaturated fatty acid, eicosapentaenoic acid (EPA), attenuated loss of body weight and significantly suppressed protein catabolism in soleus muscles through an inhibition of an ATP-dependent proteolytic pathway. The ATP-ubiquitin-dependent proteolytic pathway is considered to play a major role in muscle catabolism in cachexia, and functional proteasome activity, as determined by "chymotrypsin-like" enzyme activity, was significantly elevated in gastrocnemius muscle of mice bearing the MAC16 tumor as weight loss progressed. When animals bearing the MAC16 tumor were treated with EPA, functional proteasome activity was completely suppressed, together with attenuation of the expression of 20S proteasome -subunits and the p42 regulator, whereas there was no effect on the expression of the ubiquitin-conjugating enzyme (E2_14k). These results suggest that EPA induces an attenuation of the up-regulation of proteasome expression in cachectic mice, and this was correlated with an increase in myosin expression, confirming retention of contractile proteins. EPA also inhibited growth of the MAC16 tumor in a dose-dependent manner, and this correlated with suppression of the expression of the 20S proteasome -subunits in tumor cells, suggesting that this may be the mechanism of tumor growth inhibition. Thus EPA antagonizes loss of skeletal muscle proteins in cancer cachexia by down-regulation of proteasome expression, and this may also be the mechanism for inhibition of tumor growth.

This article has been cited by other articles:

				I. Rieu, H. Magne, I. Savary-Auzeloux, J. Averous, Céc. Bos, M. A. Peyron, L. Combaret, and D. Dardevet Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats J. Physiol., November 15, 2009; 587(22): 5483 - 5492. [Abstract] [Full Text] [PDF]

				E. Castillero, A. I. Martin, M. Lopez-Menduina, M. A. Villanua, and A. Lopez-Calderon Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1322 - R1331. [Abstract] [Full Text] [PDF]

				M. J. Tisdale Mechanisms of Cancer Cachexia Physiol Rev, April 1, 2009; 89(2): 381 - 410. [Abstract] [Full Text] [PDF]

				H. L. Eley, S. T. Russell, J. H. Baxter, P. Mukerji, and M. J. Tisdale Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E923 - E931. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Toward a Core Nutraceutical Program for Cancer Management Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF]

				R. Siddiqui, D. Pandya, K. Harvey, and G. P. Zaloga Nutrition Modulation of Cachexia/Proteolysis Nutr Clin Pract, April 1, 2006; 21(2): 155 - 167. [Abstract] [Full Text] [PDF]

				M. J. Tisdale Clinical Anticachexia Treatments Nutr Clin Pract, April 1, 2006; 21(2): 168 - 174. [Abstract] [Full Text] [PDF]

				A. Jatoi {Omega}-3 Fatty Acid Supplements for Cancer-Associated Weight Loss Nutr Clin Pract, August 1, 2005; 20(4): 394 - 399. [Abstract] [Full Text] [PDF]

				T. A. Babcock, T. Dekoj, and N. J. Espat Experimental Studies Defining {omega}-3 Fatty Acid Antiinflammatory Mechanisms and Abrogation of Tumor-Related Syndromes Nutr Clin Pract, February 1, 2005; 20(1): 62 - 74. [Abstract] [Full Text] [PDF]

				H. J. Smith, P. Mukerji, and M. J. Tisdale Attenuation of Proteasome-Induced Proteolysis in Skeletal Muscle by {beta}-Hydroxy-{beta}-Methylbutyrate in Cancer-Induced Muscle Loss Cancer Res., January 1, 2005; 65(1): 277 - 283. [Abstract] [Full Text] [PDF]

				H. J. Smith, S. M. Wyke, and M. J. Tisdale Mechanism of the Attenuation of Proteolysis-Inducing Factor Stimulated Protein Degradation in Muscle by {beta}-Hydroxy-{beta}-Methylbutyrate Cancer Res., December 1, 2004; 64(23): 8731 - 8735. [Abstract] [Full Text] [PDF]

				S. Busquets, M. T. Figueras, G. Fuster, V. Almendro, R. Moore-Carrasco, E. Ametller, J. M. Argiles, and F. J. Lopez-Soriano Anticachectic Effects of Formoterol: A Drug for Potential Treatment of Muscle Wasting Cancer Res., September 15, 2004; 64(18): 6725 - 6731. [Abstract] [Full Text] [PDF]

				P. Benatti, G. Peluso, R. Nicolai, and M. Calvani Polyunsaturated Fatty Acids: Biochemical, Nutritional and Epigenetic Properties J. Am. Coll. Nutr., August 1, 2004; 23(4): 281 - 302. [Abstract] [Full Text] [PDF]

				A. Jatoi, K. Rowland, C. L. Loprinzi, J. A. Sloan, S. R. Dakhil, N. MacDonald, B. Gagnon, P. J. Novotny, J. A. Mailliard, T. I.L. Bushey, et al. An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort J. Clin. Oncol., June 15, 2004; 22(12): 2469 - 2476. [Abstract] [Full Text] [PDF]

				E. Bruera, F. Strasser, J. L. Palmer, J. Willey, K. Calder, G. Amyotte, and V. Baracos Effect of Fish Oil on Appetite and Other Symptoms in Patients With Advanced Cancer and Anorexia/Cachexia: A Double-Blind, Placebo-Controlled Study J. Clin. Oncol., January 1, 2003; 21(1): 129 - 134. [Abstract] [Full Text] [PDF]

				O. A. J. Adegoke, N. Bedard, H. P. Roest, and S. S. Wing Ubiquitin-conjugating enzyme E214k/HR6B is dispensable for increased protein catabolism in muscle of fasted mice Am J Physiol Endocrinol Metab, September 1, 2002; 283(3): E482 - E489. [Abstract] [Full Text] [PDF]